Humana price target raised to $340 from $315 at Raymond James on EPS outlook

Raymond James raised its price target on Humana (NYSE:HUM) to $340 from $315, maintaining an Outperform rating, following the health insurer's investor day where it detailed EPS targets through 2028. The firm's analysis incorporated a scenario balancing Humana's ambitious $40 EPS target against a conservative $26 EPS estimate based on current Star ratings, highlighting that improving Star ratings could significantly boost EPS and that much of this risk is already priced into the stock, which trades at approximately 9 times the conservative estimate. This positive sentiment is echoed by other firms like Bernstein and RBC Capital, who also maintain Outperform ratings, underscoring optimism for Humana's Medicare Advantage outlook and long-term growth despite acknowledged near-term challenges.

Analysis

Raymond James has raised its price target on Humana to $340, maintaining an Outperform rating, a decision primarily influenced by the company's long-term earnings guidance presented at its recent investor day. The firm's valuation thesis hinges on a scenario analysis of Humana's 2028 earnings per share (EPS), contrasting an ambitious $40 target with a more conservative $26 estimate. The key driver for this potential upside is the improvement of its Medicare Advantage Star ratings, with a move from 25% to 75% of members in 4-Star plans projected to contribute approximately $14 to EPS. Raymond James posits that much of this operational risk is already reflected in the stock's valuation, which currently trades at a modest 9 times the conservative $26 EPS forecast. This bullish sentiment is largely shared by Bernstein and RBC Capital, who also hold Outperform ratings based on the Medicare Advantage outlook and long-term growth strategy. While TD Cowen remains more cautious with a Hold rating, it acknowledges the company's strategic efforts to restore margins. Beyond financial targets, Humana is also addressing non-financial factors by enhancing its ESG profile through new climate commitments and engaging with regulators to streamline prior authorization processes, signaling a comprehensive approach to long-term value creation.

Key Decisions for Investors

• Given that Humana's stock trades at approximately 9 times a conservative 2028 EPS estimate, investors with a long-term outlook may find the current valuation attractive, as it appears to discount the significant upside potential from improving Star ratings.
• Investors should closely monitor the company's progress on improving its Medicare Advantage Star ratings, as this is the primary operational lever identified to unlock a potential $14 in additional EPS by 2028.
• Despite the positive analyst consensus, it is crucial to remain vigilant about potential risks to enterprise-wide margin expansion and near-term challenges within the Medicare Advantage sector, which could impede the company's path to its long-term earnings targets.
• For investors with an ESG mandate, Humana’s new climate commitments and its proactive engagement on simplifying prior authorization processes represent positive steps in managing non-financial risks and could be factored into a holistic assessment of the company.